Immunogenicity, Reactogenicity and Safety of the Oral Live Attenuated Human Rotavirus Vaccine RIX4414(Rotarix? Oral Suspension (Liquid Formulation) in Vietnamese Infants

摘要

Background: The lyophilized formulation of an oral, live attenuated human rotavirus (RV) vaccine RIX4414 (Rotarix, a trademark from GlaxoSmithKline) given concomitantly with routine vaccines, has been shown to be highly immunogenic. A phase II, randomised, double-blind, placebo-controlled study (105722/NCT00345956) was conducted in Vietnam to assess the immunogenicity, reactogenicity and safety of two doses of RIX4414 oral suspension(liquid formulation) co-administered in two different schedules with routine EPI vaccines.